Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

A new guideline for treating obesity in children and adolescents says medication can be helpful, but that health providers should prioritize addressing nutrition, exercise and psychological needs. ...